Predictive Potential of RNA Polymerase B (II) Subunit 1 (RPB1) Cytoplasmic Aggregation for Neoadjuvant Chemotherapy...

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Co-translational protein aggregation is linked to altered translation regulation.
• This altered regulation may buffer transcription during genotoxic stress.
• RPB1 (RNA polymerase II largest subunit) aggregation is a potential indicator.

Purpose of the Study:

• To investigate the role of co-translational protein aggregation in tumor chemotherapy resistance.
• To assess cytoplasmic RPB1 aggregation as a predictive biomarker for neoadjuvant chemotherapy response.

Main Methods:

• Analysis of biopsy samples from patients with invasive carcinoma.
• Monitoring cytoplasmic aggregation of RPB1.
• Correlating RPB1 aggregation size with tumor regression post-therapy.

Main Results:

• Cytoplasmic RPB1 foci were observed in tumor biopsy samples.
• Larger RPB1 foci correlated with tumors showing no regression after therapy.
• RPB1 aggregation was previously linked to impaired HSP90 function or ribosome mutations.

Conclusions:

• Cytoplasmic RPB1 aggregation is associated with chemotherapy resistance.
• Monitoring RPB1 aggregation in pre-treatment biopsies may predict neoadjuvant chemotherapy effectiveness.
• RPB1 aggregation serves as a potential biomarker for treatment response in invasive carcinoma.